# Terremoto Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/terremoto-biosciences

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.terremotobio.com
- Total disclosed funding: $291M
- Latest round: Series C (Apr 15, 2026)
- Investors on record: 10

## About

Based in California, US, and founded in 2021 by its CEO, Peter Thompson, and co-founders Matthew Jacobson and Jack Taunton, Terremoto Biosciences Inc. operates as a biotechnology company that leverages lysine-based covalency to develop optimized medicines. In April 2026, Terremoto Biosciences Inc. raised USD 108 million in series C funding from RA Capital Management, Deep Track Capital, BeOne Medicines Ltd., and OUP (Osage University Partners), with participation from OrbiMed Advisors, Third Rock Ventures, Novo Holdings, and Cormorant Asset Management. 

Terremoto Biosciences Inc.'s lysine-targeted covalency platform discovers and develops drugs that covalently bind to lysine, an amino acid that is ubiquitous across the proteome and present in nearly every protein of interest. While the abundance of lysine has previously prevented the field from developing medicines that are sufficiently selective and targeted. The platform utilizes structure-based drug design, screening platform development, cryo-electron microscopy, X-ray crystallography, electrophilic warhead library development, and a computational discovery engine. 

The company plans to use the April 2026 funding to advance its lead AKT1-selective inhibitor programs through Phase 1 clinical development for cancer and hereditary hemorrhagic telangiectasia.

## Funding rounds

- Series C, Apr 15, 2026, $41M — OrbiMed Advisors, Novo Holdings, OUP (Osage University Partners), Third Rock Ventures, RA Capital Management, Cormorant Asset Management, Deep Track Capital, BeOne Medicines Ltd.
- Series B, Nov 2, 2023, $175M — OrbiMed Advisors, Novo Holdings, Third Rock Ventures, EcoR1 Capital, Cormorant Capital
- Series A, May 25, 2022, $75M — OrbiMed Advisors, Third Rock Ventures

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B, Series C
- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A, Series B, Series C
- Novo Holdings — Series B, Series C
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series B
- Cormorant Capital — Series B
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series C
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series C
- BeOne Medicines Ltd. — Series C